| Jeb A Sorom, MD | |
|
820 N Chelan Ave, Wenatchee, WA 98801-2028 | |
| (509) 663-8711 | |
| Not Available |
| Full Name | Jeb A Sorom |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 32 Years |
| Location | 820 N Chelan Ave, Wenatchee, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073568424 | NPI | - | NPPES |
| 1073568424 | Medicaid | WA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | MD00044802 (Washington) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Central Washington Hospital | Wenatchee, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Central Washington Health Services Association | 4880504596 | 645 |
News Archive
In the week that the standardised tobacco packaging regulations passed into law, the UK Department of Health has been recognised as an International Tobacco Control Leader by the American Cancer Society.
Participation in weight-bearing exercise such as running or football significantly counteracts the effects of sedentary behaviors in adolescent girls, say researchers.
Trubion Pharmaceuticals, Inc. today announced the acceptance of two Phase 1 data presentations on SBI-087 (PF-05230895) at the 2010 annual congress of the European League Against Rheumatism (EULAR) in Rome, Italy. Presentations will include promising data from a Phase 1 study of SBI-087 for the treatment of rheumatoid arthritis (RA) and a Phase 1 study of SBI-087 for the treatment of systemic lupus erythematosus (SLE). Copies of both abstracts are available at http://www.eular.org. SBI-087 is Trubion's next-generation CD20-directed small modular immunopharmaceutical (SMIP™) product candidate and is being developed in collaboration with Pfizer.
Approximately 200,000 of the 38 million people in the U.S. who take statins to treat high cholesterol may develop life-threatening muscle disease.
› Verified 6 days ago
| Entity Name | Central Washington Health Services Association |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801937453 PECOS PAC ID: 4880504596 Enrollment ID: O20031106000287 |
News Archive
In the week that the standardised tobacco packaging regulations passed into law, the UK Department of Health has been recognised as an International Tobacco Control Leader by the American Cancer Society.
Participation in weight-bearing exercise such as running or football significantly counteracts the effects of sedentary behaviors in adolescent girls, say researchers.
Trubion Pharmaceuticals, Inc. today announced the acceptance of two Phase 1 data presentations on SBI-087 (PF-05230895) at the 2010 annual congress of the European League Against Rheumatism (EULAR) in Rome, Italy. Presentations will include promising data from a Phase 1 study of SBI-087 for the treatment of rheumatoid arthritis (RA) and a Phase 1 study of SBI-087 for the treatment of systemic lupus erythematosus (SLE). Copies of both abstracts are available at http://www.eular.org. SBI-087 is Trubion's next-generation CD20-directed small modular immunopharmaceutical (SMIP™) product candidate and is being developed in collaboration with Pfizer.
Approximately 200,000 of the 38 million people in the U.S. who take statins to treat high cholesterol may develop life-threatening muscle disease.
› Verified 6 days ago
| Entity Name | Wenatchee Valley Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669719688 PECOS PAC ID: 9537309869 Enrollment ID: O20130716000034 |
News Archive
In the week that the standardised tobacco packaging regulations passed into law, the UK Department of Health has been recognised as an International Tobacco Control Leader by the American Cancer Society.
Participation in weight-bearing exercise such as running or football significantly counteracts the effects of sedentary behaviors in adolescent girls, say researchers.
Trubion Pharmaceuticals, Inc. today announced the acceptance of two Phase 1 data presentations on SBI-087 (PF-05230895) at the 2010 annual congress of the European League Against Rheumatism (EULAR) in Rome, Italy. Presentations will include promising data from a Phase 1 study of SBI-087 for the treatment of rheumatoid arthritis (RA) and a Phase 1 study of SBI-087 for the treatment of systemic lupus erythematosus (SLE). Copies of both abstracts are available at http://www.eular.org. SBI-087 is Trubion's next-generation CD20-directed small modular immunopharmaceutical (SMIP™) product candidate and is being developed in collaboration with Pfizer.
Approximately 200,000 of the 38 million people in the U.S. who take statins to treat high cholesterol may develop life-threatening muscle disease.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jeb A Sorom, MD 820 N Chelan Ave, Wenatchee, WA 98801-2028 Ph: (509) 663-8711 | Jeb A Sorom, MD 820 N Chelan Ave, Wenatchee, WA 98801-2028 Ph: (509) 663-8711 |
News Archive
In the week that the standardised tobacco packaging regulations passed into law, the UK Department of Health has been recognised as an International Tobacco Control Leader by the American Cancer Society.
Participation in weight-bearing exercise such as running or football significantly counteracts the effects of sedentary behaviors in adolescent girls, say researchers.
Trubion Pharmaceuticals, Inc. today announced the acceptance of two Phase 1 data presentations on SBI-087 (PF-05230895) at the 2010 annual congress of the European League Against Rheumatism (EULAR) in Rome, Italy. Presentations will include promising data from a Phase 1 study of SBI-087 for the treatment of rheumatoid arthritis (RA) and a Phase 1 study of SBI-087 for the treatment of systemic lupus erythematosus (SLE). Copies of both abstracts are available at http://www.eular.org. SBI-087 is Trubion's next-generation CD20-directed small modular immunopharmaceutical (SMIP™) product candidate and is being developed in collaboration with Pfizer.
Approximately 200,000 of the 38 million people in the U.S. who take statins to treat high cholesterol may develop life-threatening muscle disease.
› Verified 6 days ago
Deborah M. Witham, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 820 N Chelan Ave, Wenatchee, WA 98801 Phone: 509-663-8711 | |
David C. Wiggum, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 820 N Chelan Ave, Wenatchee, WA 98801 Phone: 509-663-8711 | |
Garrett Wolter, D.O. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 820 N Chelan Ave, Wenatchee, WA 98801 Phone: 509-663-8711 | |
Dr. Rudy Wayne Linterman, D.O. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 820 N Chelan Ave, Wenatchee, WA 98801 Phone: 509-663-8711 | |
John F. Colpitts, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 820 N Chelan Ave, Wenatchee, WA 98801 Phone: 509-663-8711 | |
Peter W. Valaas, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 820 N Chelan Ave, Wenatchee, WA 98801 Phone: 509-663-8711 |